drugset / Trial / NCT05801146
Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the efficacy and safety of HG102 for moderate to severe Glabellar Lines, non-inferiority compared to Botox® was confirmed and safety was evaluated.
Timeline
- Start
- 2024-01-04
- Primary completion
- 2025-03
- Completion
- 2025-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 20 unknown | — |
| Subject | HG102 | Unknown | 20 unknown | — |
Indications
No indication recorded.